High sodium intake, glomerular hyperfiltration and protein catabolism in patients with essential hypertension by Rossitto, Giacomo et al.
CVR-2020-0297 
High Sodium Intake, Glomerular Hyperfiltration and Protein Catabolism in 
Patients with Essential Hypertension 
Giacomo Rossitto, MD1,2; Giuseppe Maiolino, MD, PhD2; Silvia Lerco, MD2; Giulio Ceolotto, PhD2; 
Gavin Blackburn, PhD3; Sheon Mary, PhD1; Giorgia Antonelli, PhD4; Chiara Berton2; Valeria 
Bisogni, MD2; Maurizio Cesari, MD2; Teresa Maria Seccia, MD, PhD2; Livia Lenzini, PhD2; Alessio 
Pinato4; Augusto Montezano, PhD1; Rhian M. Touyz, MBBCh, PhD, FRCP, FRSE, FMedSci1; Mark 
C. Petrie, MD1; Ronan Daly, PhD3; Paul Welsh, PhD1; Mario Plebani, MD, FRCPath4; Gian Paolo 
Rossi, MD, FACC, FAHA2# and Christian Delles, MD, FRCP, FAHA1# 
1 Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow UK 
2 Clinica dell’Ipertensione, DIMED, University of Padua, Padua, Italy 
3 Glasgow Polyomics, University of Glasgow, Glasgow, UK 
4 Laboratory Medicine, DIMED, University of Padua, Padua, Italy 
# These authors equally contributed to this work 
Short title: Sodium intake and energy metabolism  
Word count: total = 7261; manuscript = 4142.  
References = 50. Figures = 3 + 1 Graphical Abstract. Tables = 2.  
 
Corresponding author: 
Giacomo Rossitto 
CoRe Clinical Research Fellow 
Institute of Cardiovascular and Medical Sciences, University of Glasgow 
BHF Glasgow Cardiovascular Research Centre 
126 University Place, G12 8TA Glasgow  
e-mail: Giacomo.Rossitto@glasgow.ac.uk 
Phone: (+44) 0141 330 2627 
The University of Glasgow, Charity Number: SC004401
Manuscript
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of 
Cardiology.  
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article/doi/10.1093/cvr/cvaa205/5872526 by guest on 11 August 2020
CVR-2020-0297 
2 
 
ABSTRACT 
Aims A blood pressure-independent metabolic shift toward a catabolic state upon high sodium (Na+) 
diet, ultimately favouring body fluid preservation, has recently been described in pre-clinical 
controlled settings. We sought to investigate the real-life impact of high Na+ intake on measures of 
renal Na+/water handling and metabolic signatures, as surrogates for cardiovascular risk, in 
hypertensive patients. 
Methods and results. We analysed clinical and biochemical data from 766 consecutive patients with 
essential hypertension, collected at the time of screening for secondary causes. The systematic 
screening protocol included 24h urine collection on usual diet and avoidance of renin-angiotensin-
aldosterone system-confounding medications. Urinary 24h-Na+ excretion, used to define classes of 
Na+ intake (Low ≤2.3g/d; Medium 2.3-5g/d; High >5g/d), was an independent predictor of glomerular 
filtration rate after correction for age, sex, blood pressure, BMI, aldosterone and potassium excretion 
(p=0.001; Low: 94.1 [69.9-118.8] vs High: 127.5 [108.3-147.8] ml/min/1.73m2). Renal Na+ and water 
handling diverged, with higher fractional excretion of Na+  and lower fractional excretion of water  in 
those with evidence of High Na+ intake (FENa: Low 0.39% [0.30-0.47] vs. High 0.81% [0.73-0.98], 
p<0.001; FEwater: Low 1.13% [0.73-1.72] vs. High 0.89% [0.69-1.12], p=0.015). Despite higher FENa, 
these patients showed higher absolute 24h Na+ reabsorption and higher associated tubular energy 
expenditure, estimated by tubular Na+/ATP stoichiometry, accordingly (ΔHigh-Low = 18 [12-24] 
kcal/d, p<0.001). At non-targeted LC/MS plasma metabolomics in an unselected subcohort (n=67), 
metabolites which were more abundant in High vs. Low Na+ intake (p<0.05) mostly entailed 
intermediates or end products of protein catabolism/urea cycle. 
Conclusions. When exposed to high Na+ intake, kidneys dissociate Na+ and water handling. In 
hypertensive patients, this comes at the cost of higher glomerular filtration rate, increased tubular 
energy expenditure and protein catabolism from endogenous (muscle) or excess exogenous (dietary) 
sources. Glomerular hyperfiltration and the metabolic shift may have broad implications on global 
cardiovascular risk independent of blood pressure. 
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TRANSLATIONAL PERSPECTIVE 
We herein show that high Na intake can adversely impact not only blood pressure control, but 
also renal function and metabolic balance in hypertensive patients. At variance with 
experimental preclinical studies, the catabolism of proteins appears to include also exogenous 
sources. Interventional studies where caloric intake is controlled but not restricted may 
identify preferential metabolic handling in different subjects/populations and test the effect of 
specific dietary strategies. Similarly, the potential benefit of medications like sodium-glucose 
cotransporter (SGLT)-2 inhibitors, which are known to reduce both glomerular 
hyperfiltration and excess tubular Na+ reabsorption, in non-diabetic hypertensive patients 
deserves further investigation in relation to the described Na+-reno-metabolic mechanisms.  
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INTRODUCTION 
A close association between sodium (Na+) and blood pressure (BP) is well recognised, although BP 
response to increased or reduced sodium intake (salt-sensitivity) varies across populations and 
individuals.1-4 The rationale for World Health Organization reduced sodium intake recommendations 
is based on the predicted benefit in terms of incidence of cardiovascular events that would follow a 
population-level decrease in BP.3, 5 While there is reasonable agreement that high salt intake 
(generally identified as > 5 g Na+/day) is associated with worse outcomes, there is no consensus on 
the optimal range of intake and the role for its effect on BP as the sole causal determinant of 
cardiovascular events has not been proven.6-9 
Recently, an independent link between high Na+ intake and a shift in metabolism has been suggested, 
whereby a catabolic state induced by Na+ would ultimately serve preservation of body water. In 
particular, in the experimental setting of a long-term salt balance study in 10 healthy male subjects 
simulating a space flight, Rakova et al. demonstrated that endogenous water generation and accrual 
prevented extra water intake upon high salt diet.10 Further mechanistic insights from a rodent study 
pointed to urea excess as a key osmotic force to minimise water loss.11 This was achieved by renal 
urea recycling and extrarenal endogenous generation, via a salt-driven catabolic state. Based on 
evidence of increased 24h urine glucocorticoids excretion in both humans and mice, the authors 
suggested hypercortisolism to mediate this metabolic shift.10, 11  
These mechanisms, which would lead to increased cardiovascular risk regardless of BP salt-
sensitivity, lack demonstration in humans out of a dietary- and environmentally-controlled 
experimental setting. 
This study sought to investigate the impact of high salt intake on renal Na+/water handling and 
metabolism in real-life in hypertensive patients undergoing systematic biochemical screening for 
secondary causes of hypertension following a predefined standardised protocol. We herein report the 
results for the large cohort of patients who received with a final diagnosis of essential hypertension.  
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METHODS - An expanded version is available in the Online Supplement. 
1. Patients and diagnostic protocol 
The study included clinical and biochemical data from consecutive patients referred to the tertiary 
Hypertension Center of the University of Padua, who underwent a biochemical screening for 
secondary causes of hypertension and provided informed written consent (2012-2017; local biobank 
Prot.1925P/2009; international ENSAT-HT network, http://www.ensat-ht.eu/, local approval prot. 
3998/AO/16; in compliance with the Declaration of Helsinki). The screening entailed plasma 
electrolytes, aldosterone, renin, cortisol, 24h urinary Na+ and K+ excretion; additional biochemical 
data, including renal function,  24h creatinine excretion, 24h urinary catecholamines/metanephrines 
and urinary free cortisol were measured as recommended by guidelines12-15. Patients were not 
instructed to change their usual dietary habits before the screening. They were asked to undertake a 
24h urine collection on the day before and to bring the entire volume on the morning of blood 
sampling, which was performed after one-hour in supine position, between 8 and 10 AM. If patients 
were already treated, screening was performed after appropriate washout from agents affecting the 
renin-angiotensin-aldosterone system and switch to calcium channels blockers and/or doxazosin, as 
per guidelines,13 unless contraindicated. Exclusion criteria entailed reported/biochemical evidence of 
oral, intramuscular or intravenous steroid use or abuse and cases with a final diagnosis of secondary 
hypertension after appropriate work-up (biochemistry, anatomical/functional imaging, adrenal/renal 
vein sampling) and follow-up at the time of data-lock (1st January 2019). Patients with a conclusive 
diagnosis of essential hypertension were grouped according to classes of Na+ intake. Intake estimates 
were based on 24u-Na+-excretion, which has limitations when applied to a single subject16 but is only 
minimally affected by within-individual day-to-day variability when applied to groups with sufficient 
number of participants included.17 Intakes were defined as low ≤2.3g Na+/d (100 mmol/d); medium 
2.3-5g Na+/d; high >5g Na+/d (216 mmol/d; Figure S1), according to commonly used cut-offs.18, 19 
2. Laboratory methods 
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Plasma and urinary electrolytes, plasma renin, aldosterone and cortisol, and additional biochemistry as 
appropriate and detailed above, were measured at the time of the secondary hypertension screening in 
an International Standard Organisation (ISO) 15189:2012 accredited clinical laboratory (University of 
Padua) by routine methods. Normal values and within‐ and inter-assay coefficient of variation for 
aldosterone and renin, as well as aldosterone-to-renin ratio (ARR) criteria for primary aldosteronism 
and further diagnostic work-up have already been reported13, 20, 21 and are recapitulated in the Online 
Supplement. Plasma cortisol concentration was measured by a chemiluminescence competitive 
immunoassay and urinary 24h free cortisol (UFC) by a LC-MS/MS, as described in detail 
elsewhere.22, 23 Urinary catecholamines and metanephrines were measured by HPLC with 
electrochemical detection with a CE-IVD kit (Online Supplement).  
Plasma and 24h urinary urea and creatinine were not routinely determined in all screened patients; the 
available biochemical dataset was expanded by analysing urine samples stored in the local biobank 
since the time of the screening and validating the results against the original dataset according to 
Passing & Bablok method (Figure S2-S4 and Table S1).  
3. Renal function and energetics 
Urine samples collected over the 24h immediately before plasma sampling were used for estimation 
of glomerular and tubular function, according to standard equations. In particular, glomerular 
filtration rate (GFR) was estimated by 24h creatinine clearance and also by the CKD-EPI formula.24 
Tubular Na+ handling was assessed by fractional excretions (i.e. the percentage of the filtered amount 
that is excreted), as well as the absolute amount of filtered, reabsorbed, and excreted Na+ (mmol/day). 
Fractional excretion of water (FEWater) was calculated as urine flow rate/GFR. Estimated tubular 
energy expenditure (kcal/d) was calculated based on a tubular 4.6 Na+/ATP stoichiometry and the free 
energy equivalent of ATP.25 
4. Metabolomics 
Available EDTA-plasma samples from a non-selected sub-cohort of patients in the low and the high 
Na+ intake groups, stored in Padua biobank from the time of screening, were extracted with 
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chloroform/methanol/water (1:3:1 v/v) and stored at −80 °C until analysis by liquid chromatography – 
mass spectrometry (LC-MS). Briefly, samples were eluted on a hydrophilic interaction liquid 
chromatography column (ZIC-pHILIC, Merck) and analysed on a Thermo Q-Exactive (Thermo 
Scientific), operated in polarity switching mode to record both positive and negative ionisation mode 
data for each sample. A pooled sample, prepared by combining an aliquot from each individual 
sample, was injected every 5th injection to confirm the stability of the analysis. The raw MS data was 
processed in a non-targeted way, using a pipeline consisting of XCMS (peak picking) and MZMatch 
(grouping and filtering).26-30 
5. Statistics 
Categorical variables are presented as absolute numbers and percentages and compared by χ2 test. 
Quantitative variables were tested for normal distribution in the whole cohort and in individual groups 
by graphical plot and Kolmogorov–Smirnov test; they are presented as mean ± SD, or median and 
interquartile range in case of a skewed distribution. Parametric and nonparametric statistics were used 
for normally and non-normally distributed variables, respectively. In particular, one-way analysis of 
variance (ANOVA) or Kruskal-Wallis test was used to compare anthropometric, clinical, and 
biochemical data across study groups, with Tukey or Dunn’s as post-hoc tests, as appropriate; crude 
correlations were ascertained by Pearson or Spearman tests.  
Multivariable-adjusted comparisons (ANCOVA) and linear regression models included significant 
covariates identified at comparison of Na-intake groups, i.e. age, sex, BMI, aldosterone and systolic 
blood pressure, upon appropriate transformation to attain normal distribution. Little’s Missing 
Completely At Random (MCAR) test was used beforehand to test the assumption that variables were 
missing completely at random, including the above covariates and urinary (u-) Na+ excretion in the 
analysis; no imputation methods were adopted and missing data were excluded, with valid numbers 
for each analysis reported in the manuscript.  
Slopes of the regression lines for fractional excretions, assessing tubular Na+ and water handling, were 
compared between high and low Na+ intake groups using the extra-sum-of-squares F test, with 
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automatic outliers exclusion (conservative Q for ROUT approach set at 0.5%) and normality of 
residuals confirmed with Kolmogorov–Smirnov test.  
For metabolomics, the intensity of peaks with a matching database formula 31 was log transformed 
and t-test comparisons were conducted between high and low Na+ intake groups, using a moderated 
linear model. The p-values for the targeted and non-targeted analysis were corrected to control the 
false discovery rate.32  
The α level was set at 0.05 and all statistical tests were 2-tailed. SPSS (version 25, IBM) and Prism 
(version 8.02, GraphPad Software) were used for the analysis.  
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RESULTS 
1. Cohort characteristics 
Out of 1464 patients, we excluded 592 in whom washout of confounding medications was not 
possible and 106 who received a final diagnosis of secondary hypertension (Figure S1). The final 
study cohort therefore included data from 766 patients, almost exclusively of Caucasian ethnicity. 
Their clinical and biochemical general characteristics by Na+ intake groups are reported in Table 1. Of 
note, pre-defined 24 u-Na+ cut-off values for group allocation closely approximated the extreme 
quintiles of the distribution (102 and 219 mmol/day for 20th and 80th percentile, respectively).  
Patients on high Na+ intake were generally younger, had a higher BMI and similar BP values, 
although more frequently required doxazosin on top of a first-line calcium channel blocker, compared 
with other Na+ groups. Prevalence of diabetes and/or CKD (KDIGO stage ≥ 3) in the cohort was low 
(<4% for both) and did not differ across study groups.  
While plasma Na+ and K+ did not differ, plasma aldosterone was higher with low Na+ intake 
(p=0.040). Renin showed a similar trend, which reached statistical significance upon correction for 
age and sex, significant predictors at multivariate regression analysis (Tables S2-S3 and Figures S5-
S6).  Overall, the aldosterone-to-renin ratio did not differ across study groups. In the 24h urine, higher 
Na+ excretion was paralleled by a higher K+ excretion and total urinary volume (p<0.001 for both).  
2. Renal Na+ and water handling 
We first tested the association between the fractional excretions (FE) of Na+ and water (n=282, 
Little’s MCAR test Sig.=0.185 and n=303, Sig.=0.163, respectively), as expression of the traditional 
osmotic natriuresis mechanism challenged by Rakova et al.10  In the context of an expected positive 
correlation (Spearman ρ=0.402, p<0.001), the slope of the regression line was steeper at low 
compared to high salt intake (p=0.005; Figure 1, panel A). In fact, the FE of Na+ increased with 
increasing Na+ intake (p<0.001 across groups; post-hoc low vs. high: 0.39% [0.30-0.47] vs. 0.81% 
[0.73-0.98], p<0.001) while that of water decreased (p=0.016 across groups; post-hoc low vs. high: 
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1.13% [0.73-1.72] vs. 0.89% [0.69-1.12], p=0.015; Figure 1, panel B). No such difference was 
observed for K+ FE (p=0.892).  
To dissect the determinants of the above differences, we compared glomerular filtration rates and 
absolute measures of tubular activity across study groups. 
3. Excess Na excretion is paralleled by glomerular hyperfiltration 
In keeping with evidence of a higher excretion of creatinine in the 24 h, BSA-corrected (and 
uncorrected) creatinine clearance was greater in high than in medium- and low-Na+ intake (p<0.001 
across groups; n=249; Little’s MCAR test Sig.=0.221; Table 2). In the High Na+ group 36.7% of the 
patients met the definition of “glomerular hyperfiltration” according to a commonly used cut-off (135 
ml/min/1.73m2),33, 34 compared to 16.4 and 8.2% in the Medium and Low Na+ intake group, 
respectively (χ2, p<0.001). Similar trends were confirmed with use of CKD-EPI formula, although 
with lower estimates of eGFR and of glomerular hyperfiltration prevalence, accordingly (Table 2 and 
S4). 
An independent association between 24h urinary Na+ excretion and creatinine clearance was 
confirmed at multivariate regression analysis, after correction for age, sex, systolic blood pressure, 
BMI, and aldosterone (p<0.001). In a regression model including also 24h urinary K+, as an 
independent surrogate marker for global food intake based on the above demonstration of a constant 
tubule handling, both variables remained significant predictors (p=0.003 and p<0.001, respectively; 
Tables S5-S6).  
4. High Na+ Intake increases tubular reabsorption and renal energy expenditure 
Although the FE was higher with high Na+ intake, the total amount of Na+ filtered by the glomerulus 
and reabsorbed by the tubules per day was far larger compared to medium and low Na+ intake 
(p<0.001, regardless of adjustment for the above covariates, including stratification by sex; Figure 2, 
panel A and Table S4). 
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The estimated energy cost for this excess reabsorptive tubular activity is shown in Figure 2, panel B 
(Δ high vs. low Na+ intake groups=18 [12-24] kcal/day; p<0.001). 
Urinary norepinephrine excretion, as a surrogate measure of renal sympathetic nerve activity 
contribution to tubular Na+ reabsorption,35, 36 increased across groups of Na+ intake (p<0.001) and was 
independently associated with 24h-uNa+ excretion (Figure S7, Tables S7-S10). 
5. Re-setting of nitrogen balance and metabolic signatures  
While 24h-urine excretion data suggested a higher daily loss of both creatinine and urea with high Na+ 
intake (p≤0.001 for both), plasma values increased or did not differ, respectively (Table 2). No 
difference in the FE of urea was observed across groups (p=0.724). Overall, this suggested a global 
re-setting of the nitrogen balance.  
Analysis of non-targeted metabolomics showed that the majority of metabolites significantly 
increased in the High Na+ (n=35) compared to Low Na+ group (n=32) entailed intermediates or end 
products of protein catabolism (i.e. dipeptides, single amino acids or their derivatives) or urea cycle 
(N-Acetyl-L-glutamate 5-semialdehyde: fold change (FC)=1.52, pcorr=0.02; Figure 3, panel B). In 
particular, plasma levels of detectable amino acids (including the branched-chain leucine, isoleucine, 
and valine and with the exception of few conditionally-essential or non-essential aminoacids) were 
increased with High Na+ intake (Figure 3, panel B).  
Other significantly increased metabolites identified by the non-targeted approach included products of 
triglycerides and fatty acid metabolism (diacylglycerols and acyl-glycines), acyl-carnitines and some 
industrial food/tobacco-related compounds (Figure 3 panel A). A complete list of significantly 
different metabolites is provided in the online supplement (Table S11).     
While no obvious shift in carbohydrate metabolism was observed at metabolomics analysis, higher 
Na+ intake was associated with higher plasma glucose (n=171; High Na+: 4.9 [4.6-5.4] mmol/l, 
Medium Na+: 4.7 [4.3-5.0] mmol/l, Low Na+: 4.5 [4.2-5.0] mmol/l; p=0.004) and insulin (n=47; High 
Na+: 7.46 [4.75-11.80] U/ml, Medium Na+: 5.81 [3.79-9.24] U/ml, Low Na+: 4.89 [3.72-8.04] 
U/ml; p=0.001); however, these associations did not persist at multivariable analysis, where BMI 
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stood out as the strongest common independent predictor (r=0.38, p=0.002 and r=0.48, p<0.001 
respectively; Tables S12-S15). 
6. Excess cortisol excretion upon high Na+ intake  
We additionally explored whether cortisol excess could be a primary drive for muscle catabolism 
upon High Na+ intake, as suggested previously.11 In our study, 24h urinary free cortisol (UFC) 
increased across groups of Na+ intake (n=137, Little’s MCAR test Sig.=0.161; Low Na+: 63 [36-72] 
nmol, Medium Na+: 60 [47-86] nmol, High Na+: 86 [75-139] nmol; p<0.001). The positive association 
of UFC with 24h-uNa+ excretion persisted at multivariable analysis after correction for age, sex, 
systolic blood pressure, BMI, and aldosterone (p=0.017), and also for creatinine clearance (p=0.035); 
however, the latter stood out as the strongest independent predictor (p<0.001; Tables S16-S17).  
Morning plasma-cortisol showed an opposite trend (n=658; Low Na+: 246 [203-309] nmol/l, Medium 
Na+: 238 [194-294] nmol/l, High Na+: 217 [171-294] nmol/l; p=0.047); no independent association 
with 24h-uNa+ was observed (p=0.284; Tables S18-S19).   
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DISCUSSION 
Our study examined the hypothesis that high Na+ intake could induce mechanisms of water 
preservation and adversely affect metabolic signatures, surrogates for global cardiovascular risk, in a 
large real-life population of hypertensive patients. This idea was first proposed by Titze et al. based 
on the diet-controlled experimental settings of a rodent study and a long-term simulated space flight 
of 10 healthy subjects.10, 11 Our results, obtained under normal dietary conditions and salt excretions 
comparable to those reported in other populations17, showed that the higher excretion of Na+ was 
indeed coupled with a higher excretion of water, in keeping with the classic concept of osmotic 
natriuresis. However, we identified opposite trends relative to their filtered amount: while the 
fractional excretion increased for Na+ upon high Na+ intake, it decreased for water and this was 
paralleled by a plasma metabolomic signature consistent with protein catabolism and with the results 
obtained by Titze et al in rodent models. These findings indicate that kidneys can effectively 
dissociate Na+ and water handling upon high Na+ intake and that the associated catabolic state, likely 
participating in this water preservation mechanism, could independently affect the risk of 
cardiovascular disease. 
Previous clinical studies suggested a different body water handling, assessed as body weight change 
and diuretic response upon salt load and depletion, between salt-sensitive and salt-resistant 
(insensitive) subjects.37 Our study, albeit lacking a formal assessment of salt sensitivity, rather focused 
on the renal-specific differential regulation of Na+/water excretion and its correlates, independently of 
blood pressure (Tables S5 and S6). Such fine regulation relies upon a larger amount of processed 
urine and a higher GFR. A recent meta-analysis identified this association also in interventional 
trials,38 but was limited in its conclusions by the heterogeneity in study designs, populations and 
approaches to estimation of GFR. In the present study we employed a standardised screening 
approach and a rigorous protocol that included washout of confounding medications, the use of 24h 
urine collections for the assessment of both Na+ and creatinine excretion and non-targeted 
metabolomics. In a large sample size we showed that a considerable proportion of patients exhibit 
glomerular hyperfiltration upon high Na+ intake: although estimates differ depending on the method 
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used for GFR assessment,24 this proportion is consistently higher compared to both medium and low 
Na+ groups. Glomerular hyperfiltration, traditionally linked to obesity and diabetes,33 is a recognised 
marker of early kidney damage, precedes microalbuminuria and/or decline in renal function and 
predicts cardiovascular events.34 Our study suggests Na+ intake, independent of blood pressure values 
and of a surrogate for total food consumption, as a key determinant in the pathogenesis of glomerular 
hyperfiltration in hypertension, thus confirming previous suggestions from a smaller study.39 
While higher filtration carries the ultimate advantage of more precise distal regulation of solutes,40 not 
only has it negative long-term prognostic implications, but also comes at the cost of a much higher 
tubular activity at more proximal segments (Figure 2). The increase in Na+ reabsorption in response to 
the increased filtered Na+ load is known as glomerulo-tubular balance and is primarily active via 
Na+/K+ ATPase, with ancillary passive mechanisms facilitated by changes in tubular, interstitial and 
capillary physical forces. The extra Na+/K+ ATPase activity implicates a higher oxygen and energy 
consumption.41 Pruijm et al. found that one week of high-Na+ diet reduced renal medullary 
oxygenation in both normotensive and hypertensive subjects by using blood oxygen level-dependent 
(BOLD) MRI,42 thus pointing to a higher oxygen extraction by tubular cells, which ultimately 
supports our contentions.  
Our estimate of the excess energy cost upon high vs low Na+ intake was 18 kcal. This is a rough 
(potentially over- or under-) estimate, based on a stoichiometry value that averages different tubular 
segments with different activity and was validated in ‘standard’ conditions.25 Albeit imprecise, it 
offers an order of magnitude that corresponds approximately to 4.5 g of protein or 2 g of fat per day. 
These values should be considered in a lifespan or population perspective. Of note, with the due 
haemo- and tubule-dynamic corrections required between species, the magnitude of this energy cost 
well justifies the weight loss observed in high Na+-fed mice when their total caloric food intake was 
paired with low Na+-fed controls.11 In that animal model, the catabolic state primarily oriented toward 
protein degradation and muscle loss served to generate both endogenous water and osmotically-active 
urea. Overall, these mechanisms allowed water preservation against Na+ excess and a potentially 
volume-depleting osmotic diuresis.11 In our study, a similar re-setting in nitrogen balance was 
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observed: along with evidence of massive excretions of urea and creatinine upon high Na+ intake, we 
identified a catabolic signature at non-targeted metabolomics, mostly entailing intermediates or end 
products of the urea cycle or protein catabolism. In particular, plasma levels of all the identifiable 
essential aminoacids were increased, thus ruling out endogenous generation or the sole renal recycling 
as sources for their excess. To the best our knowledge, this is the first metabolomics approach to the 
topic of salt balance in humans. 
Based on the increase in 24h urinary glucocorticoid excretion upon High Na+ diet, Titze et al. 
suggested a Na+-induced subclinical hypercortisolism as the intermediate determinant of the above 
catabolic state.10, 11 In our human cohort we could not confirm a cortisol increase in plasma. The UFC 
excretion, although increased and independently associated with Na+ excretion, had GFR as its 
strongest predictor and its increase was clinically trivial, particularly when GFR-adjusted. This 
appears in keeping with human physiological studies assessing the renal clearance of plasma 
cortisol,43 or UFC excretion in other glomerular hyperfiltration-associated conditions, like obesity 44 or 
simple water load.45 In fact, only subtle increases in adrenal cortisol secretion in response to Na+ 
loading, possibly due to the cross stimulation of the hypothalamic-pituitary-adrenal axis by the water-
preserving vasopressin,46 were observed by Ehrlich et al. despite marked changes in urinary 
excretion.47 As discussed above, we propose that glomerular hyperfiltration and the consequent 
glomerulo-tubular balance per se would suffice to induce extra energy requirements and the 
development of a catabolic state.  
The main limitation of our study is its cross-sectional nature, unsuitable to prove causality. However, 
mechanistic evidence of a metabolic shift had already been provided in preclinical models11 and our 
study has the advantage to offer a perspective on real-life, where caloric and/or water intake is not 
restricted or fixed. Obviously, this prevented discrimination as to how this energy cost, predominantly 
but not exclusively in the form of protein, was paid. Although the association between Na+ intake and 
renal haemodynamics/energetics was independent of K+ excretion, a crude surrogate for total food 
intake, this could reflect catabolism of either endogenous (muscle mass) or exogenous (dietary 
excess) sources. Based on the higher BMI and a larger urea clearance in our high Na+ group, we 
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speculate that both options could be exploited to different degrees in different individuals, according 
to multiple determinants. These would include cultural and socio-economical aspects, favouring or 
limiting food access. In this regard, the per-protocol controlled caloric intake in the 10 healthy male 
cosmonauts could account for the reduced excretion and increased recycling of urea observed in the 
original study by Rakova et al,10 but not in our real-life cohort. Similarly, it could account for the 
discrepancy of those preclinical data with the recent findings by Juraschek et al, who found increased 
thirst upon high Na+ diet in a secondary analysis of the randomised DASH-Sodium trial, where caloric 
intake was not fixed.48 Juraschek et al also provided reassurance against a putative weight gain effect 
of low salt intake, if endogenous sources were the only available for Na+-induced catabolism.  At 
variance, they could not draw definite conclusions regarding high Na+ intake, since the trial failed at 
adjusting the energy intake of participants to maintain a stable weight, further confounded by 
unmeasured fluid retention.  
Overall, the importance of an altered caloric balance is such that the excess exploitation of exogenous 
protein sources would ultimately result in excess fat deposition regardless of food relative 
composition.49 Therefore, excess food consumption and lean mass loss, alternative or complementary 
sources for the catabolic state observed in our study, are both likely to favour a long-term adverse 
insulin-resistant metabolic phenotype, universally associated to worse cardiovascular outcomes.  
Additional limitations of the study include: use of a single 24-hour urine collection, which might not 
accurately estimate an individual’s usual long-term daily sodium intake; missing data that potentially 
reduced the power of some analyses, e.g. for UFC; the lack of a formal BP “salt-sensitivity” 
assessment in the protocol, as mentioned, as well as the ethnicity distribution of our almost 
exclusively Caucasian cohort, which might require validation in other groups like African-Americans. 
However, estimates of intake by 24-hour urine collections in properly sized groups are not 
significantly affected by random variability across individuals, 17 particularly when they are not 
instructed to artificially change their dietary habits. Moreover, use of the same 24 urine samples for 
the assessment of all renal handling parameters provides an intra-patient control, with all fluctuations 
going in the same biological direction and, overall, levelling off in large numbers. Finally, absence of 
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evidence of systematic bias and strong statistical significance for most of our results makes type II 
error or any considerable impact of missing data on the overall message unlikely.  
In conclusion, our results confirmed the activation of water-preserving mechanisms upon high Na+ 
intake in a large real-life cohort of patients with essential hypertension. These mechanisms appear to 
involve glomerular hyperfiltration, enhanced glomerulo-tubular balance, increased tubular energy 
expenditure and protein catabolism, with broad implications on cardiovascular risk. The preferential 
endogenous or exogenous source of protein to compensate for these energy costs in different 
subjects/populations remain to be established in interventional studies, where caloric intake is 
controlled but not restricted. However, it is already tempting to speculate that specific dietary 
strategies and/or novel medications like SGLT-2 inhibitors, reducing both glomerular hyperfiltration 
and the energy-demanding tubular Na+ reabsorption, could favorably impact the metabolic 
consequences of excess Na+ intake and the global risk profile of hypertensive patients.  
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FIGURE 1. Renal Na and Water handling upon differential Na+ intake. 
Panel A) the positive association between Water and Na+ fractional excretions (FE) reflects he 
osmotic effect of Na+, driving a parallel excretion of accompanying water (ntot=282); however, the 
slope of this association is steeper at low (white dots; n=61) compared to high (red dots; n=63) Na+ 
intake (1.62 [95%CI: 1.14-2.09] vs 0.81 [95%CI: 0.56-1.06], respectively; p=0.005, extra-sum-of-
squares F test; X indicate automatically-excluded outliers [ROUT approach, Q=0.5%] from High and 
Low Na+ intake groups). Panel B) with increasing Na+ intake, Na+ FE increases while water FE 
decreases (Kruskall-Wallis test: p<0.001 and p=0.017, respectively; Dunn’s post-hoc test results on 
top of bars); no significant difference across groups was noted for K+. Cases are the same as for panel 
A; n>60 per bar. Data are shown as median and IQR; * p<0.05, ** p<0.01; **** p<0.0001. 
FIGURE 2. Absolute Na+ excretion and reabsorption and energy cost.  
Panel A) The total excreted Na+ (shaded bars) is a trivial proportion of the reabsorbed amount; the 
latter is much higher upon high Na+ intake and resulted in 18 kcal of estimated excess energy 
expenditure per day (Panel B). Data are shown as median and IQR; ntot=282, nlow Na=61, nhigh Na=63. 
Kruskall-Wallis and Dunn’s post-hoc tests: ** p<0.01; *** p<0.001. 
FIGURE 3. Metabolomics signature.  
Panel A) Volcano plot showing the metabolomics comparison between High and Low (reference) Na+ 
intake (ntot=67 subjects; nlowNa=32, nHighNa = 35). Y axis: uncorrected p values; curved lines: multiple 
comparisons-corrected significance (pcorr<0.05). Red dots: intermediates/end products of the urea 
cycle or protein catabolism; empty dots: other identified metabolites, please see Table S11 in the 
Supplement). Panel B) comparative profile of plasma aminoacids LC/MS signals (mean, 95%CI); for 
visualisation, the x scale was made homogeneous by Z-score transformation, based on mean and SD 
from the low Na+ group, as a reference; n=35 (High Na). Background: white = essential aminoacids; 
light grey = conditionally essential, dark grey = dispensable aminoacids. Bars: dashed for branched-
chain aminoacids; red for significance (pcorr < 0.05). Peaks for asparagine, Cysteine, Glutamine and 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article/doi/10.1093/cvr/cvaa205/5872526 by guest on 11 August 2020
CVR-2020-0297 
25 
 
Methionine could not be unequivocally identified. For all statistical comparisons, log-transformed 
peak intensities of the n=67 subjects were compared by t-tests with a false-discovery-rate correction. 
FIGURE 4. Summary figure. 
High salt intake is traditionally linked to cardiovascular risk via its effect on blood pressure (BP, in 
grey). Preclinical studies recently described a metabolic shift toward catabolism upon high sodium 
(Na+) diet, ultimately favouring body water preservation and possibly impacting cardiovascular risk, 
irrespective of BP. In a large cohort of hypertensive patients we confirmed that kidneys preserve 
water and excrete sodium excess upon high salt intake; this was associated with glomerular 
hyperfiltration, higher tubular workload and a plasma metabolomic signature suggestive of protein 
catabolism. Muscle loss and/or excess food consumption, paralleled by adverse renal haemodynamics 
in a putative vicious circle, could represent a novel BP-independent link between salt intake and 
cardiovascular disease. 
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Table 1 – Clinical and biochemical characteristics of patients, by Na+ intake group 
 nvalid whole cohort Low-Na+ (n=146) Medium-Na+ (n=464) High-Na+ (n=156) p 
Age (years)  766 47 ± 13 47 ± 13 47 ± 13 44 ± 13 *† 0.015 
Sex (M; n/%) 766 428 / 55.9% 49 / 33.6% 248 / 53.4%* 132 / 84.1% *† < 0.001 
BMI (Kg/m2) 537 25.6 [23.0-29.0] 24.1 [21.0-27.4] 25.7 [23.2-29.1]* 26.7 [24.5-29.8] *† < 0.001 
SBP (mmHg) 647 150 ± 18 153 ± 20 149 ± 18 149 ± 15  0.165 
DBP (mmHg) 647 93 ± 10 93 ± 10 93 ± 10 94 ± 11 0.801 
Medications:       
  none (n/%) 766 138 / 18.0% 27 / 18.5% 89 / 19.2% 22 / 14.0% 0.356 
  dihydropiridine CCB (n/%) 766 444 / 58.0% 82 / 56.2% 261 / 56.3% 102 / 65% 0.158 
  non-dihydropiridine CCB (n/%) 766 160 / 20.9% 30 / 20.5% 103 / 22.2% 27 / 17.2% 0.427 
  α-blockers (n/%) 766 173 / 22.6% 24 / 16.4% 102 / 22.0%* 47 / 29.9% *† 0.016 
Diabetes (n/%) 630 24 / 3.8% 4 / 3.3% 15 / 4.0% 5 / 3.6% 0.927 
Chronic Kidney Disease (n/%) 645 24 / 3.7% 4 / 3.3% 18 / 4.7% 2 / 1.4% 0.222 
p-Na+ (mmol/l) 675 141 ± 2 141 ± 2 141 ± 2 141 ± 2 0.650 
p-K+ (mmol/l) 703 4.0 ± 0.4 4.0 ± 0.4 4.1 ± 0.4 4.0 ± 0.4 0.070 
PAC (pmol/l) 766 241 [183-340] 265 [ 189-386] 232 [182-323]* 254 [174-344]* 0.040 
PRA (ng/ml/h), 2012-2015 313 0.64 [0.33-1.26] 1.00 [0.29-1.50] 0.61 [0.30-1.21] 0.62 [0.41-1.17] 0.361 
DRC (mIU/L), 2015-2017 452 7.9 [3.3-14.8] 9.5 [4.1-15.9] 7.7 [3.1-13.6] 7.6 [2.7-15.7] 0.155 
ARRPRA (ng/dl/ ng/ml/h) 313 15.9 [9.1-29.4] 14.9 [9.1-29.7] 16.5 [8.2-31.2] 15.7 [9.8-24.7] 0.823 
ARRDRC (ng/dl/ mIU/L) 452 1.09 [0.61-2.25] 0.99 [0.62-2.00] 1.14 [0.62-2.46] 1.03 [0.53-2.15] 0.514 
24h-u-Diuresis (L/d) 766 1.8 [ 1.4-2.3] 1.5 [1.0-2.1] 1.8 [1.4-2.3]* 2.0 [1.6-2.4] *† < 0.001 
24h-u-Na+ (mmol/d) 766 155 [112-205] 80 [66-92] 154 [128-183]* 252 [236-294] *† < 0.001 
24h-u-K+ (mmol/d) 766 60 [48-77] 49 [38-65] 60 [48-74]* 73 [61-90] *† < 0.001 
nvalid = number of patients with available information. BMI = Body Mass Index; SBP and DBP = systolic and diastolic blood pressure, 
respectively; CCB = calcium channel blockers; p- = plasma; 24h-u- = 24 h urine; PAC  = plasma aldosterone concentration; PRA plasma renin 
activity; DRC = direct renin concentration; ARR = aldosterone-to-renin ratio. Post-hoc tests: * p < 0.05 vs Low-Na+; † p < 0.05 vs Medium-Na+  
Table 1
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Table 2 – Renal function by Na+ intake group  
p- = plasma; u- = urine. GFR = Glomerular filtration rate. BSA = body surface area. padj = analysis of variance adjusted for age, sex, systolic blood pressure, BMI 
and aldosterone. Post-hoc tests:* p < 0.05 vs Low-Na+;  † p < 0.05 vs Medium-Na+ . padj = sig. corrected for age, sex, systolic blood pressure, BMI, and 
aldosterone. 
 
 nvalid whole cohort Low-Na+ Medium-Na+ High-Na+ p padj 
p-Creatinine (μmol/l) 664 73 [63-84] 69 [59-78] 73 [63-84]* 75 [68-85] * 0.002 0.027 
u-Creatinine (mmol/l) 325 7.0 [5.0-10.4] 5.7 [4.1-9.4] 6.7 [4.6-10.3] 9.1 [6.3-10.5] *† 0.001 < 0.001 
24h u-Creatinine excretion (mmol/d) 325 12.0 [8.8-15.6] 8.8 [7.1-11.9] 11.7 [8.9-15.3]* 16.0 [13.9-19.7] *† < 0.001 < 0.001 
Estimated GFR:        
Creatinine Clearance (ml/min) 303 119.2 [93.0-151.1] 100.5 [75.1-117.8] 116.6 [91.7-142.4]* 150.3 [125.6-178.1] *† < 0.001 < 0.001 
Creatinine Clearance/BSA (ml/min/1.73m2) 249 108.6 [86.7-128.8] 94.1 [69.9-118.8] 103.8 [86.9-126.0]* 127.5 [108.3-147.8] *† < 0.001 < 0.001 
Glomerular hyperfiltration - n/tot (%)  48/249 (19.3%) 5/61 (8.2%) 21/128 (16.4%) 22/60 (36.7%) *† < 0.001  
eGFR – CKD-EPI (ml/min/1.73m2) 664 98.4 [86.6-107.6] 98.8 [86.8-106.0] 97.0 [85.4-106.3] 100.8 [91.4-111.7] *† 0.001 0.02 
Glomerular hyperfiltration - n/tot (%)  8/664 (1.2%) 0/122 (0%) 3/405 (0.7%) 5/137 (3.6%) * 0.011  
p-Urea (mmol/l) 498 4.8 [4.0-5.7] 4.7 [4.0-5.6] 4.7 [3.9-5.6] 5.1 [4.2-6.1] † 0.026 0.724 
u-Urea (mmol/l) 173 196.6 [127.2-271.3] 145.5 [100.3-237.4] 177.4 [125.9-257.8] 260.2 [177.9-314.1] *† 0.001 0.015 
24h-u-Urea excretion (mmol/d) 173 337.5 [239.6-499.0] 242.9 [178.3-343.0] 332.1 [244.8-453.9]* 496.8 [373.0-610.6] *† < 0.001 < 0.001 
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